# Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

> **NCT01658579** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 59 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** HOE901-U300 (new formulation of insulin glargine)
- **DRUG:** Lantus (insulin glargine)

## Key facts

- **NCT ID:** NCT01658579
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2015-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01658579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01658579, "Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01658579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*